A Cautionary Tale: The Rise of GLP-1s
This brief underscores the history of GLP-1 medications and makes policy recommendations to ensure patients are receiving the right drugs at the right time.
This brief underscores the history of GLP-1 medications and makes policy recommendations to ensure patients are receiving the right drugs at the right time.
By offering lower costs, more benefits and better outcomes, Medicare Advantage is increasingly becoming the Choice of America’s Seniors.
ACHP issued a statement in response to CMS’ CY 2025 Advance Notice for Medicare Advantage and Part D.
ACHP submitted a response to an RFI from the National Institute of Standards and Technology on the exercise of march-in rights.
ACHP submitted a response to an RFI from Senator Bill Cassidy (R-LA) on access to cell and gene therapies.
ACHP is the voice of a unique approach in health care today, one that puts the patient at the center with plans and clinical teams collaborating to improve health outcomes and reduce costs. Our advocacy focuses on providing policymakers with tested solutions, rooted in a model that is proven to deliver better value for patients, employers and taxpayers.